Table 1

Baseline characteristics: nivolumab plus TACE versus nivolumab only

Nivolumab and TACE (n=31)Nivolumab only (n=93)
OS-matched
P valueNivolumab only (n=62)
PFS-matched
P value
Age (SD)65.0 (13.8)64.8 (10.4)0.0866.4 (10.6)0.56
Female (%)4 (13)19 (20)0.3514 (16)0.68
Liver disease*
 HBV (%)9 (29)36 (39)0.3926 (27)>0.99
 HCV (%)9 (29)31 (33)0.8321 (34)0.81
 EtOH (%)6 (19)16 (17)0.7917 (27)0.45
 NASH (%)5 (16)11 (12)0.549 (15)>0.99
 Other (%)3 (9.7)1 (1.1)0.048*0 (0)0.003*
Child-Pugh0.920.10
 A25 (81)76 (82)39 (61)
 B5 (16)15 (16)20 (34)
 C1 (3.2)2 (2.0)3 (4.8)
PS ECOG0.190.18
 0–131 (100)85 (91)62 (93)
 >108 (8.6)5 (7.5)
BCLC0.050.006*
 A2 (6.4)12 (13)11 (18)
 B10 (32)43 (46)32 (52)
 C18 (58)36 (39)17 (27)
 D1 (3.2)2 (2)2 (3)
AFP >400 (%)5 (16)16 (17)>0.9910 (16)>0.99
ALBI grade†1.7 (0.6)2.6 (0.9)<0.0012.2 (0.9)0.008
PVT3 (9.7)8 (8.6)>0.996 (9.7)>0.99
Metastases8 (26)24 (26)>0.9916 (26)>0.99
Max tumor diameter, median (IQR)2.8 (1.7–6.2)4.2 (2.2–7.8)0.254.2 (2.4–7.5)0.24
 Median number of Nodules (IQR)3 (2–3)2 (1–4)0.261 (1–4)0.04*
 Milan criteria8 (26)25 (27)>0.9921 (34)0.48
Prior treatments
 Surgery13 (42)31 (33)0.4019 (31)0.36
 Ablation4 (13)29 (31)0.0623 (37)0.017*
 TACE12 (39)52 (56)0.1038 (62)0.04
 TARE1 (3.2)18 (19)0.04*12 (19)0.05
 Sorafenib3 (9.7)57 (61)<0.0001*32 (52)<0.0001*
 RT1 (3.2)12 (13)0.187 (11)0.26
  • *Patients in combined treatment and matched groups could have multiple liver disease etiologies.

  • †ALBI scores were missing in 20% of the monotherapy cohort.

  • AFP, alpha fetoprotein; ALBI, albumin–bilirubin; BCLC, Barcelona Clinic Liver Classification; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; EtOH, alcoholic cirrhosis; HBC, hepatitis C virus; HBV, hepatitis B virus; NASH, non-alcoholic steatohepatitis; OS, overall survival; PFS, progression-free survival; PVT, portal vein thrombosis; RT, radiation therapy; TACE, transarterial chemoembolization; TARE, transarterial radioembolization.